{"product_id":"lilly-bcg-matrix","title":"Eli Lilly Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEli Lilly’s BCG Matrix preview shows which drugs are driving growth and which might be holding you back — a quick lens on Stars, Cash Cows, Question Marks, and Dogs. Want the full picture? Purchase the complete BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word + Excel files to guide investment and portfolio decisions. Get instant clarity and skip the guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMounjaro (tirzepatide) — T2D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMounjaro (tirzepatide) is a BCG Star: runaway 2024 demand and a fat order book fuel massive share in injectable T2D\/weight markets. Clinical and real-world data show up to 1.8–2.0% HbA1c reduction and SURMOUNT-1 weight loss to 22.5%, underpinning sustained uptake. Continued value depends on aggressive supply build-out and global rollout muscle to avoid shortages. Keep feeding it and it prints the next decade.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZepbound (tirzepatide) — Obesity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZepbound (tirzepatide) — approved by the FDA for chronic weight management on November 8, 2023 — has driven explosive category-defining demand and cultural momentum, quickly taking high share in a still-accelerating obesity market. Marketing, payer access negotiations, and rapid manufacturing scale-up require heavy ongoing investment to sustain growth and convert market lead into a long-term annuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerzenio (abemaciclib) — HR+\/HER2− breast cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerzenio (abemaciclib) has strong guideline presence after FDA adjuvant approval in 2021 based on monarchE, and is endorsed in major guidelines such as NCCN and ESMO for HR+\/HER2− high‑risk disease.\u003c\/p\u003e\n\u003cp\u003eIt is gaining share within the still‑growing CDK4\/6 class versus competitors but requires continued confirmatory evidence and geographic label expansions to defend market position.\u003c\/p\u003e\n\u003cp\u003eOngoing investment in trials, real‑world evidence generation and global rollout is required to keep uptake and revenue trajectory rising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJardiance (empagliflozin) — cardio-renal-metabolic (alliance)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCategory leader with broad labels and durable physician habit; alliance Jardiance recorded roughly $10 billion global sales in 2024 and continues double-digit volume growth across HF, CKD and T2D. Market still growing: SGLT2 class expected mid-to-high single-digit CAGR, driven by expanding HF\/CKD indications and rising prescriptions. Co-promote economics improve with scale; keep flywheel spinning via outcomes readouts and access wins. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eleader\u003c\/li\u003e\n\u003cli\u003e~$10B 2024 sales\u003c\/li\u003e\n\u003cli\u003eexpanding HF\/CKD\/T2D labels\u003c\/li\u003e\n\u003cli\u003eco-promote economics scale\u003c\/li\u003e\n\u003cli\u003efocus on outcomes \u0026amp; access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaltz (ixekizumab) — Immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTaltz (ixekizumab) remains a Star for Eli Lilly with leading share in psoriasis and axial spondyloarthritis and healthy new-start volumes in 2024; IL-17 biologics continue double-digit market growth as biologic penetration rises. Competitive landscape is intense but patient retention is high once responders achieve remission; focus on speed of onset and superior skin clearance sustains differentiation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: strong new-start momentum, double-digit class growth\u003c\/li\u003e\n\u003cli\u003eHigh market share across psoriasis and axSpA\u003c\/li\u003e\n\u003cli\u003eSticky adherence once patients respond\u003c\/li\u003e\n\u003cli\u003eKey differentiator: rapid onset and skin clearance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 leaders fuel demand; oncology\/IL-17 champs expand; SGLT2 hits \u003cstrong\u003e$10B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMounjaro and Zepbound are Stars: category-defining demand and rapid uptake in T2D\/obesity; scale-up and supply are critical. Verzenio and Taltz hold high share in growing oncology and IL‑17 markets but need ongoing evidence and geographic expansion. Jardiance remains a durable Star with ~$10B global sales in 2024, driving SGLT2 class growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003eRunaway demand, supply focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003eFDA 11\/8\/2023; rapid uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio\u003c\/td\u003e\n\u003ctd\u003eGuideline\/adjuvant traction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaltz\u003c\/td\u003e\n\u003ctd\u003eLeading share, double‑digit class growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJardiance\u003c\/td\u003e\n\u003ctd\u003e~$10B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix of Eli Lilly's portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Eli Lilly BCG Matrix exposing portfolio pain points with clear actions for faster strategic fixes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrulicity (dulaglutide)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrulicity (dulaglutide) remains a cash cow for Eli Lilly with 2024 global sales around $6.6 billion, reflecting a large installed base and strong brand recognition. Growth has slowed as prescribers migrate to next‑gen incretins, but it still throws off meaningful cash and supports margins. Minimal promotion beyond retention and access is required; milk while carefully managing formulary erosion and lifecycle defense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumalog\/Humulin — legacy insulins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumalog\/Humulin are mature, price‑pressured legacy insulins but deliver reliable volume supported by global diabetes prevalence (IDF \u0026gt;537 million adults, 2021) and remain stable cash contributors with limited upside. The Medicare Part D insulin cap of $35\/month (effective 2023) sustains pricing pressure into 2024. Operational efficiency—manufacturing optimization and noise minimization—drives margin improvement more than promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasaglar\/Rezvoglar (insulin glargine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBasaglar and Rezvoglar anchor Lilly’s insulin glargine biosimilar presence in a mature, low-growth basal insulin basin, delivering predictable, payer-driven volumes tied to formulary placement.\u003c\/p\u003e\n\u003cp\u003eLean manufacturing and tight SG\u0026amp;A control convert steady unit demand into cash generation rather than growth spend.\u003c\/p\u003e\n\u003cp\u003ePriority: defend formulary wins, optimize rebate economics, and let the product run as a margin-preserving cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlumiant (baricitinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOlumiant (baricitinib) sits as a cash cow for Eli Lilly with mixed indications across rheumatoid arthritis and dermatology, supporting a stable base in a mature JAK inhibitor class; 2024 net sales reported around $3.4 billion, reflecting limited growth but steady recurring revenue and low incremental investment needs, so Lilly appears to be harvesting while monitoring class dynamics and regulatory\/competitive shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMixed indications: RA, dermatology\u003c\/li\u003e\n\u003cli\u003e2024 sales: ≈ $3.4B\u003c\/li\u003e\n\u003cli\u003eLow incremental CAPEX; stable cash flow\u003c\/li\u003e\n\u003cli\u003eStrategy: harvest; monitor class\/regs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmgality (galcanezumab) — Migraine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmgality (galcanezumab) remains a well-known migraine CGRP monoclonal antibody with steady refill dynamics in a crowded field; market growth began moderating by 2024 but Emgality’s share has stayed reasonably durable. Promotion can be targeted rather than broad, supporting high unit margins and disciplined commercial spend, making it a classic Eli Lilly cash cow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved 2018\u003c\/li\u003e\n\u003cli\u003eCompetes vs Aimovig, Ajovy, Vyepti\u003c\/li\u003e\n\u003cli\u003eSteady refills, moderated market growth (2024)\u003c\/li\u003e\n\u003cli\u003eFocused promotion, strong margin profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtect formularies, optimize rebates, defend $6.6B and $3.4B cash cows and insulin revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrulicity ($6.6B 2024) and Olumiant ($3.4B 2024) are primary cash cows, yielding steady margins despite slowed growth. Legacy insulins (Humalog\/Humulin) and Basaglar\/Rezvoglar provide predictable volumes under pricing pressure. Emgality sustains refill revenue with targeted promotion. Focus: defend formularies, optimize rebates, minimize incremental investment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrulicity\u003c\/td\u003e\n\u003ctd\u003e$6.6B\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eInstalled base, retention focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlumiant\u003c\/td\u003e\n\u003ctd\u003e$3.4B\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eStable RA\/derm revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulins\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eVolume, price pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmgality\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eDurable refills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eEli Lilly BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Eli Lilly BCG Matrix you'll receive after purchase—no watermarks, no placeholders. This exact, professionally formatted report maps Lilly's portfolios into Stars, Cash Cows, Question Marks, and Dogs, ready for strategy use. Once bought, the full document is yours to download, edit, and present—no surprises, just clean, market-informed analysis. Use it straightaway in planning or investor decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlimta (pemetrexed)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlimta (pemetrexed) has seen its patent-protected position eroded by generic entrants, and by 2024 those headwinds have materially lowered pricing and demand. Revenues are drifting while incremental investment yields poor payback, leaving cash tied up with low ROI. Given portfolio priorities at Eli Lilly, Alimta is a prime candidate for continued trimming and redeployment of capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy COVID antibodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDogs: Legacy COVID antibodies — clinical utility has sunset as variants displaced activity; U.S. government procurement largely ended after 2022 and by 2024 sales were negligible, providing minimal revenue while residual manufacturing and regulatory complexity persists. No turnaround story here; exit costs have been pared and resources refocused on higher-growth franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCymbalta (duloxetine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCymbalta (duloxetine) went off‑patent in the US with generic entry after 2013 and by 2024 is generically available worldwide, leaving only a residual sales tail. It holds little to no strategic value for Eli Lilly’s growth agenda and should be treated as a low‑priority BCG dog. It can consume disproportionate management attention if not kept lean; deprioritize marketing and minimize fixed costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZyprexa (olanzapine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZyprexa (olanzapine) lost primary US patent protection in 2011 and faces widespread generic olanzapine competition; sales have sharply declined and it no longer functions as a growth platform for Eli Lilly. Given low margins and overhead, it is break-even at best; strategy: maintain minimal regulatory and safety compliance and reallocate resources.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent expiry: 2011\u003c\/li\u003e\n\u003cli\u003eGenerics: widespread since post-2011\u003c\/li\u003e\n\u003cli\u003eFinancial stance: low-margin, decline\u003c\/li\u003e\n\u003cli\u003eAction: minimal compliance, de-prioritize\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvista\/Forteo and other long-tail brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvista\/Forteo and other long-tail Lilly brands are fragmented, low-growth, low-share leftovers that together represent a low single-digit percent of Eli Lillys 2024 revenue; the osteoporosis and niche endocrinology segments grew below 3% in 2024. Overmanaging these assets creates operational drag and margin erosion; maintain reliable supply and minimal marketing spend. Divest when market bids reflect strategic value, not sentiment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFragmented, low-share\u003c\/li\u003e\n\u003cli\u003eSub-3% segment growth (2024)\u003c\/li\u003e\n\u003cli\u003eLow single-digit percent of Lilly 2024 revenue\u003c\/li\u003e\n\u003cli\u003eKeep supply reliable, limit Ops\u003c\/li\u003e\n\u003cli\u003eDivest when price is right\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrim legacy drugs in 2024: minimize spend, maintain compliance, redeploy capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs (Alimta, legacy COVID mAbs, Cymbalta, Zyprexa, Evista\/Forteo) are low-share, low-growth in 2024; combined ~low-single-digit percent of Eli Lilly 2024 revenue and segment growth \u0026lt;3% in 2024. Sales\/price pressure from generics and variant displacement left revenues negligible or declining by 2024. Strategy: minimize spend, maintain compliance, redeploy capital to growth franchises.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003cth\u003eRevenue impact\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlimta\u003c\/td\u003e\n\u003ctd\u003eGeneric erosion\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003ctd\u003eTrim\/redeploy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID mAbs\u003c\/td\u003e\n\u003ctd\u003eClinical utility sunset\u003c\/td\u003e\n\u003ctd\u003eNegligible by 2024\u003c\/td\u003e\n\u003ctd\u003eExit\/reduce\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCymbalta\u003c\/td\u003e\n\u003ctd\u003eGeneric worldwide\u003c\/td\u003e\n\u003ctd\u003eResidual tail\u003c\/td\u003e\n\u003ctd\u003eMinimize ops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZyprexa\u003c\/td\u003e\n\u003ctd\u003eGeneric competition\u003c\/td\u003e\n\u003ctd\u003eLow-margin\u003c\/td\u003e\n\u003ctd\u003eMaintain compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisunla (donanemab) — Alzheimer’s\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKisunla (donanemab) sits in Question Marks: a high-growth Alzheimer’s market with massive unmet need—about 6.7 million Americans living with Alzheimer’s (Alzheimer’s Association, 2023) and FDA approval in January 2024. Early share is constrained by required amyloid confirmation (PET\/CSF), limited infusion capacity and complex payer navigation. Launch and infrastructure costs burn cash before revenue accrues. Invest selectively to scale diagnostics, infusion sites and payer strategy to push toward Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmvoh (mirikizumab) — Ulcerative colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmvoh (mirikizumab) received FDA approval in March 2024 for moderate-to-severe ulcerative colitis after phase 3 trials demonstrated statistically significant induction remission at week 12 and durable maintenance through week 52.\u003c\/p\u003e\n\u003cp\u003eThe drug launches into a crowded biologic class (anti-TNFs, anti-integrins, anti-ILs) where initial share will hinge on rapid clinician adoption and payer access wins.\u003c\/p\u003e\n\u003cp\u003ePriority: spend selectively on clear differentiation and generate real-world evidence to accelerate uptake and justify formulary placement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetevmo (selpercatinib) — RET-driven cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetevmo (selpercatinib) shows compelling efficacy in RET-driven cancers and was FDA-approved May 8, 2020, for RET fusion-positive NSCLC and RET-mutant medullary thyroid cancer. RET fusions occur in roughly 1–2% of NSCLC and RET alterations appear in ~10–20% of thyroid cancers, so the target niche is small but clinically meaningful. Market share remains modest yet defensible if precision-dx and global expansion continue. Backing is warranted where testing infrastructure is maturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJaypirca (pirtobrutinib) — BTK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJaypirca (pirtobrutinib) shows an attractive efficacy and tolerability profile in heavily pretreated B‑cell populations, with pivotal BRUIN data showing meaningful responses in prior BTK‑exposed patients (ORR ~57% in mantle cell\/CLL cohorts reported 2023–24).\u003c\/p\u003e\n\u003cp\u003eCompetitive landscape is noisy with multiple covalent and noncovalent BTK rivals and CD20\/BTK combos accelerating, pressuring uptake.\u003c\/p\u003e\n\u003cp\u003eEarly commercial traction lags potential—2024 US sales reported by Lilly remained modest—focus should be on label expansions and KOL momentum to drive uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: profile — ORR ~57% (BRUIN, 2023–24)\u003c\/li\u003e\n\u003cli\u003eTag: competition — multiple BTK competitors intensified 2024\u003c\/li\u003e\n\u003cli\u003eTag: revenue — early 2024 US sales modest vs addressable market\u003c\/li\u003e\n\u003cli\u003eTag: strategy — prioritize label expansions and KOL engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEbglyss (lebrikizumab) — Atopic dermatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEbglyss (lebrikizumab) enters atopic dermatitis as a strong clinical package but a late entrant against incumbents dupilumab and tralokinumab; US adult AD prevalence ~7% (CDC). It needs rapid payer traction and clear positioning vs incumbents, with focused spend to win step-edits and patient starts; if uptake lags, reassess burn quickly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate entrant vs dupilumab\/tralokinumab\u003c\/li\u003e\n\u003cli\u003eStrong clinical data\u003c\/li\u003e\n\u003cli\u003eRequires payer wins and clear positioning\u003c\/li\u003e\n\u003cli\u003eSpend to drive step-edit approvals and starts\u003c\/li\u003e\n\u003cli\u003eStop-loss: reassess burn if uptake underperforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApprovals show promise, but diagnostics, infusion capacity and payers cap uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLilly Question Marks: high-growth indications with approvals (Kisunla Jan 2024, Omvoh Mar 2024) but constrained uptake by diagnostics, infusion capacity, payer access and crowded classes; selective investment in diagnostics, infusion sites, RWE and payer strategy to drive scale or cut losses.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003eAlzheimer’s\u003c\/td\u003e\n\u003ctd\u003eFDA Jan 2024\u003c\/td\u003e\n\u003ctd\u003e6.7M US pts (2023)\u003c\/td\u003e\n\u003ctd\u003eScale diagnostics\/infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmvoh\u003c\/td\u003e\n\u003ctd\u003eUC\u003c\/td\u003e\n\u003ctd\u003eFDA Mar 2024\u003c\/td\u003e\n\u003ctd\u003eClass crowding\u003c\/td\u003e\n\u003ctd\u003eRWE\/payer wins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetevmo\u003c\/td\u003e\n\u003ctd\u003eRET+ tumors\u003c\/td\u003e\n\u003ctd\u003eOn market\u003c\/td\u003e\n\u003ctd\u003eRET fusions ~1–2% NSCLC\u003c\/td\u003e\n\u003ctd\u003eExpand testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJaypirca\u003c\/td\u003e\n\u003ctd\u003eB‑cell malignancies\u003c\/td\u003e\n\u003ctd\u003eEarly sales 2024 modest\u003c\/td\u003e\n\u003ctd\u003eORR ~57%\u003c\/td\u003e\n\u003ctd\u003eLabel\/KOL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEbglyss\u003c\/td\u003e\n\u003ctd\u003eAtopic dermatitis\u003c\/td\u003e\n\u003ctd\u003eLate entrant\u003c\/td\u003e\n\u003ctd\u003eUS adult AD ~7%\u003c\/td\u003e\n\u003ctd\u003ePayer\/positioning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098168463708,"sku":"lilly-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/lilly-bcg-matrix.png?v=1781799709","url":"https:\/\/pestel-analysis.com\/products\/lilly-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}